KR20230165263A - 작용성 항-il-2r 항체 및 사용 방법 - Google Patents
작용성 항-il-2r 항체 및 사용 방법 Download PDFInfo
- Publication number
- KR20230165263A KR20230165263A KR1020237035936A KR20237035936A KR20230165263A KR 20230165263 A KR20230165263 A KR 20230165263A KR 1020237035936 A KR1020237035936 A KR 1020237035936A KR 20237035936 A KR20237035936 A KR 20237035936A KR 20230165263 A KR20230165263 A KR 20230165263A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- chain
- antibody
- sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170383P | 2021-04-02 | 2021-04-02 | |
| US63/170,383 | 2021-04-02 | ||
| US202163239883P | 2021-09-01 | 2021-09-01 | |
| US63/239,883 | 2021-09-01 | ||
| PCT/US2022/023058 WO2022212848A1 (en) | 2021-04-02 | 2022-04-01 | Agonistic anti-il-2r antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230165263A true KR20230165263A (ko) | 2023-12-05 |
Family
ID=81385128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237035936A Pending KR20230165263A (ko) | 2021-04-02 | 2022-04-01 | 작용성 항-il-2r 항체 및 사용 방법 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11884735B2 (https=) |
| EP (1) | EP4314067A1 (https=) |
| JP (1) | JP2024512982A (https=) |
| KR (1) | KR20230165263A (https=) |
| AU (1) | AU2022252398A1 (https=) |
| BR (1) | BR112023020219A2 (https=) |
| CA (1) | CA3214587A1 (https=) |
| CL (2) | CL2023002895A1 (https=) |
| CO (1) | CO2023014054A2 (https=) |
| CR (1) | CR20230507A (https=) |
| IL (1) | IL305944A (https=) |
| JO (1) | JOP20230234A1 (https=) |
| MX (1) | MX2023011624A (https=) |
| PE (1) | PE20240913A1 (https=) |
| PH (1) | PH12023552763A1 (https=) |
| TW (1) | TW202304994A (https=) |
| UY (1) | UY39715A (https=) |
| WO (1) | WO2022212848A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| TW202304994A (zh) * | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| TW202602940A (zh) | 2024-04-09 | 2026-01-16 | 美商安進公司 | 激動性抗ｉｌ－２ｒｂｇ重鏈抗體 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026033139A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| JP3255699B2 (ja) | 1992-04-23 | 2002-02-12 | 味の素株式会社 | ヒトＩＬ−２レセプターγ鎖分子 |
| US6297028B1 (en) | 1995-01-09 | 2001-10-02 | Boehringer Ingelheim International Gmbh | IL-2R-associated polypeptide and DNA molecules coding therefor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| AU2937597A (en) | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
| US6103879A (en) | 1996-06-21 | 2000-08-15 | Axys Pharmaceuticals, Inc. | Bivalent molecules that form an activating complex with an erythropoietin receptor |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004032961A1 (en) | 2002-10-10 | 2004-04-22 | Merck Patent Gmbh | Bispecific anti-erb-b antibodies and their use in tumor therapy |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| DK3725807T3 (da) | 2012-12-03 | 2026-01-12 | Novimmune Sa | Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| WO2014182970A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| EP3707162A1 (en) | 2017-11-10 | 2020-09-16 | Agency for Science, Technology and Research | Il2rbeta/common gamma chain antibodies |
| TW202031683A (zh) * | 2018-11-09 | 2020-09-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| TW202039557A (zh) * | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| WO2020160242A1 (en) | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| TW202304994A (zh) * | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
-
2022
- 2022-03-31 TW TW111112596A patent/TW202304994A/zh unknown
- 2022-04-01 MX MX2023011624A patent/MX2023011624A/es unknown
- 2022-04-01 AU AU2022252398A patent/AU2022252398A1/en active Pending
- 2022-04-01 CR CR20230507A patent/CR20230507A/es unknown
- 2022-04-01 PH PH1/2023/552763A patent/PH12023552763A1/en unknown
- 2022-04-01 JP JP2023559727A patent/JP2024512982A/ja active Pending
- 2022-04-01 UY UY0001039715A patent/UY39715A/es unknown
- 2022-04-01 PE PE2023002728A patent/PE20240913A1/es unknown
- 2022-04-01 BR BR112023020219A patent/BR112023020219A2/pt unknown
- 2022-04-01 EP EP22718473.6A patent/EP4314067A1/en active Pending
- 2022-04-01 CA CA3214587A patent/CA3214587A1/en active Pending
- 2022-04-01 WO PCT/US2022/023058 patent/WO2022212848A1/en not_active Ceased
- 2022-04-01 IL IL305944A patent/IL305944A/en unknown
- 2022-04-01 KR KR1020237035936A patent/KR20230165263A/ko active Pending
-
2023
- 2023-02-03 US US18/164,442 patent/US11884735B2/en active Active
- 2023-08-29 US US18/457,553 patent/US12590163B2/en active Active
- 2023-09-26 JO JOJO/P/2023/0234A patent/JOP20230234A1/ar unknown
- 2023-09-28 CL CL2023002895A patent/CL2023002895A1/es unknown
- 2023-10-23 CO CONC2023/0014054A patent/CO2023014054A2/es unknown
-
2025
- 2025-06-09 CL CL2025001688A patent/CL2025001688A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240913A1 (es) | 2024-04-30 |
| MX2023011624A (es) | 2023-10-11 |
| IL305944A (en) | 2023-11-01 |
| PH12023552763A1 (en) | 2024-04-15 |
| JOP20230234A1 (ar) | 2023-09-26 |
| US20240018250A1 (en) | 2024-01-18 |
| AU2022252398A9 (en) | 2024-01-11 |
| CR20230507A (es) | 2023-12-12 |
| CA3214587A1 (en) | 2022-10-06 |
| CO2023014054A2 (es) | 2023-11-10 |
| CL2025001688A1 (es) | 2025-08-18 |
| WO2022212848A1 (en) | 2022-10-06 |
| US20230242653A1 (en) | 2023-08-03 |
| EP4314067A1 (en) | 2024-02-07 |
| TW202304994A (zh) | 2023-02-01 |
| CL2023002895A1 (es) | 2024-02-02 |
| US12590163B2 (en) | 2026-03-31 |
| AU2022252398A1 (en) | 2023-09-21 |
| BR112023020219A2 (pt) | 2024-02-06 |
| UY39715A (es) | 2022-10-31 |
| US11884735B2 (en) | 2024-01-30 |
| JP2024512982A (ja) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12590163B2 (en) | Agonistic anti-IL-2R antibodies and methods of use | |
| CN113710707B (zh) | 结合于psma的重链抗体 | |
| TWI838621B (zh) | 具有經修飾重鏈恆定區之多特異性重鏈抗體 | |
| KR20230038211A (ko) | Bcma에 결합하는 다중특이적 항체 | |
| KR20230148828A (ko) | 항-psma 항체 및 car-t 구조 | |
| US20240002498A1 (en) | Heavy chain antibodies binding to folate receptor alpha | |
| KR20230150825A (ko) | 항-muc1-c 항체 및 car-t 구조 | |
| KR20230166090A (ko) | 항-cd19 항체 및 car-t 구조체 | |
| CN117337303A (zh) | 抗cd20抗体及car-t结构 | |
| US20260102487A1 (en) | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof | |
| CN117136198A (zh) | 激动性抗il-2r抗体及其使用方法 | |
| CN117120472A (zh) | 抗cd19抗体及car-t结构 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231019 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250327 Comment text: Request for Examination of Application |